Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (331-340 of 497) with videos related to

Pageof 50
Sort By:
Nature Genetics|November 1, 2001
The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNAH Mandel, R Szargel, V Labay, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Anesthesia and Analgesia|June 6, 2019
Pediatric Critical Care Anesthesiologist: Extinction Is Not an OptionJamie McElrath Schwartz, Sapna R Kudchadkar, John J McCloskey, et al.
Pediatrics|March 1, 1990
Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of ageC D Berkowitz, J I Ward, C E Chiu, et al.
The Journal of Pediatrics|April 1, 1987
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of ageC D Berkowitz, J I Ward, K Meier, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|June 14, 2003
Developmental and behavioral pediatric practice patterns and implications for the workforce: results of the Future of Pediatric Education II Survey of Sections ProjectDesmond P Kelly, Wiliam L Cull, Ethan Alexander Jewett, et al.
Vascular Health and Risk Management|April 8, 2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyBennett Levitan, Zhong Yuan, Alexander G G Turpie, et al.
Circulation|May 20, 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]D B Mark, P A Cowper, S D Berkowitz, et al.
The Journal of Bone and Joint Surgery. American Volume|October 6, 2005
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplastyClifford W Colwell, Scott D Berkowitz, Jay R Lieberman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.
Pageof 50

Showing results (331-340 of 497) with videos related to

Sort By:
Pageof 50
Nature Genetics|November 1, 2001
The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNAH Mandel, R Szargel, V Labay, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Anesthesia and Analgesia|June 6, 2019
Pediatric Critical Care Anesthesiologist: Extinction Is Not an OptionJamie McElrath Schwartz, Sapna R Kudchadkar, John J McCloskey, et al.
Pediatrics|March 1, 1990
Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of ageC D Berkowitz, J I Ward, C E Chiu, et al.
The Journal of Pediatrics|April 1, 1987
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of ageC D Berkowitz, J I Ward, K Meier, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|June 14, 2003
Developmental and behavioral pediatric practice patterns and implications for the workforce: results of the Future of Pediatric Education II Survey of Sections ProjectDesmond P Kelly, Wiliam L Cull, Ethan Alexander Jewett, et al.
Vascular Health and Risk Management|April 8, 2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyBennett Levitan, Zhong Yuan, Alexander G G Turpie, et al.
Circulation|May 20, 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]D B Mark, P A Cowper, S D Berkowitz, et al.
The Journal of Bone and Joint Surgery. American Volume|October 6, 2005
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplastyClifford W Colwell, Scott D Berkowitz, Jay R Lieberman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.
Pageof 50